Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy
Purpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation. Results: A 66-year-old female patient was treated with repeated intravitreal an...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2017-04-01
|
Series: | Case Reports in Ophthalmology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/475520 |
id |
doaj-b24758dbb25d44c986ce05ca8f25e8d0 |
---|---|
record_format |
Article |
spelling |
doaj-b24758dbb25d44c986ce05ca8f25e8d02020-11-24T23:30:58ZengKarger PublishersCase Reports in Ophthalmology1663-26992017-04-018127127810.1159/000475520475520Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF TherapyThomas BertelmannHans Ulrich FrankHendrik Ansgar FuchsNicolas FeltgenPurpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation. Results: A 66-year-old female patient was treated with repeated intravitreal anti-VEGF injections due to ischemic ME following an acute BRVO. Over a period of 2.5 years best corrected visual acuity increased from 0.06 to 0.6 (decimal notation) accompanied by a reduction in central retinal thickness from 546 to 292 µm. Overall 17 anti-VEGF injections were administered to treat repeated recurrence of ME. Macular ischemia did not worsen during this profound intravitreal anti-VEGF therapy. Conclusion: Intravitreal anti-VEGF therapy can be a beneficial treatment strategy even in ischemic ME following an acute BRVO.http://www.karger.com/Article/FullText/475520Branch retinal vein occlusionMacular ischemiaAnti-VEGFCorticosteroidsIntravitreal injectionVisual acuityCentral retinal thicknessCOMRADEMacular thickness |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Thomas Bertelmann Hans Ulrich Frank Hendrik Ansgar Fuchs Nicolas Feltgen |
spellingShingle |
Thomas Bertelmann Hans Ulrich Frank Hendrik Ansgar Fuchs Nicolas Feltgen Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy Case Reports in Ophthalmology Branch retinal vein occlusion Macular ischemia Anti-VEGF Corticosteroids Intravitreal injection Visual acuity Central retinal thickness COMRADE Macular thickness |
author_facet |
Thomas Bertelmann Hans Ulrich Frank Hendrik Ansgar Fuchs Nicolas Feltgen |
author_sort |
Thomas Bertelmann |
title |
Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy |
title_short |
Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy |
title_full |
Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy |
title_fullStr |
Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy |
title_full_unstemmed |
Branch Retinal Vein Occlusion, Macular Ischemia, and Intravitreal Anti-VEGF Therapy |
title_sort |
branch retinal vein occlusion, macular ischemia, and intravitreal anti-vegf therapy |
publisher |
Karger Publishers |
series |
Case Reports in Ophthalmology |
issn |
1663-2699 |
publishDate |
2017-04-01 |
description |
Purpose: To report a case with ischemic macular edema (ME) due to an acute branch retinal vein occlusion (BRVO) which was treated with repeated intravitreal anti-VEGF injections. Methods: Retrospective case presentation. Results: A 66-year-old female patient was treated with repeated intravitreal anti-VEGF injections due to ischemic ME following an acute BRVO. Over a period of 2.5 years best corrected visual acuity increased from 0.06 to 0.6 (decimal notation) accompanied by a reduction in central retinal thickness from 546 to 292 µm. Overall 17 anti-VEGF injections were administered to treat repeated recurrence of ME. Macular ischemia did not worsen during this profound intravitreal anti-VEGF therapy. Conclusion: Intravitreal anti-VEGF therapy can be a beneficial treatment strategy even in ischemic ME following an acute BRVO. |
topic |
Branch retinal vein occlusion Macular ischemia Anti-VEGF Corticosteroids Intravitreal injection Visual acuity Central retinal thickness COMRADE Macular thickness |
url |
http://www.karger.com/Article/FullText/475520 |
work_keys_str_mv |
AT thomasbertelmann branchretinalveinocclusionmacularischemiaandintravitrealantivegftherapy AT hansulrichfrank branchretinalveinocclusionmacularischemiaandintravitrealantivegftherapy AT hendrikansgarfuchs branchretinalveinocclusionmacularischemiaandintravitrealantivegftherapy AT nicolasfeltgen branchretinalveinocclusionmacularischemiaandintravitrealantivegftherapy |
_version_ |
1725539403815714816 |